FBPase 2 sits at a metabolic crossroads in the body, and the name itself can point to two closely related but distinct proteins. One is the fructose-2,6-bisphosphatase domain built into the bifunctional enzyme PFK-2/FBPase-2, which controls levels of a powerful glycolytic activator. The other is fructose-1,6-bisphosphatase 2 (FBP2), the muscle-specific isozyme of a gluconeogenic enzyme that has turned out to do far more than just shuffle sugar. Both proteins have become subjects of intense research interest, with roles spanning cold survival, heart protection, cancer suppression, and brain metabolism that go well beyond what anyone expected from a “mere” metabolic enzyme.
Two Proteins, One Name
The confusion around “FBPase 2” starts with naming conventions. In mammals, there are four genes encoding isoenzymes of PFK-2/FBPase-2, a homodimeric protein that carries two catalytic activities on the same polypeptide. One half (the PFK-2 domain) makes fructose-2,6-bisphosphate, a molecule that turbocharges glycolysis. The other half (the FBPase-2 domain) breaks fructose-2,6-bisphosphate down. The balance between these two activities determines how fast a cell burns glucose. In the liver isoenzyme, hormonal signals tip this balance: when the enzyme is phosphorylated by a kinase activated during fasting, its PFK-2 side shuts off and its FBPase-2 side turns on, slowing glycolysis and favoring glucose production.1Portland Press (Biochemical Journal). 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis Each of the four gene products can also generate multiple splice variants, creating a surprisingly large family of isoforms tailored to different tissues.
Separately, FBP2 (fructose-1,6-bisphosphatase 2) is a standalone enzyme once thought to exist mainly in skeletal muscle, where it converts fructose-1,6-bisphosphate back to fructose-6-phosphate during glycogen resynthesis. It is one of two isozymes of FBPase in vertebrates: FBP1 predominates in liver and kidney, while FBP2 was assumed to have a narrower job. That assumption has been thoroughly overturned, because FBP2 turns up in the nucleus, interacts with transcription factors, protects mitochondria, and acts as a tumor suppressor, all independent of its sugar-splitting catalytic activity.2PubMed Central. Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis
How FBP2 Assembles and Gets Regulated
FBP2 exists in two structural forms: dimers and tetramers. This might sound like a minor detail, but it dramatically changes what the enzyme does. The dimeric form is fully active as a catalyst and completely ignores AMP, the molecule that normally shuts FBPase down. When four subunits come together into a tetramer, the protein gains sensitivity to AMP inhibition. That tetramerization depends on a hydrophobic core region, where a single amino acid, leucine at position 190, plays a pivotal role.3PubMed Central. Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell This means the cell can control FBP2’s behavior not just by turning it on or off, but by shifting the ratio of dimers to tetramers. The dimer can interact with mitochondria and carry out non-catalytic functions, while the tetramer responds to the cell’s energy status through AMP.
FBP2 levels are also regulated after the protein is made. In oral squamous cell carcinoma, for example, a protein called TRIM32 directly binds FBP2 and tags it for destruction through ubiquitination. When TRIM32 is abundant, FBP2 gets degraded faster, and glycolysis speeds up, which benefits the tumor. Silencing TRIM32 reverses this effect, and that reversal depends specifically on FBP2 being available again.4Biochemical and Biophysical Research Communications. TRIM32 promotes oral squamous cell carcinoma progression by enhancing FBP2 ubiquitination and degradation
Keeping Warm When It Counts
One of the more unexpected roles for FBP2 is in maintaining body temperature during cold exposure. When muscles need to generate heat through shivering or non-shivering thermogenesis, they burn through glycogen rapidly. But glycogen stores are finite, and when food intake drops during prolonged cold, muscles need a way to rebuild their glycogen locally without relying entirely on glucose delivered by the blood. This process, sometimes called glyconeogenesis, converts lactate (produced by the muscle itself during contraction) back into glycogen. FBP2 is essential for this conversion.
In mice engineered to lack FBP2, the cold-induced recycling of lactate into muscle glycogen was completely abolished. Without that glycogen resupply pathway, the knockout animals could not sustain thermogenesis when external glucose was limited. These mice were unable to maintain normal body temperature under cold stress, demonstrating that FBP2 is not merely a backup pathway but a critical part of the thermal survival toolkit.5Experimental & Molecular Medicine. The essential role of fructose-1,6-bisphosphatase 2 enzyme in thermal homeostasis upon cold stress
PFKFB2 and Heart Metabolism
The heart is metabolically flexible: it switches between burning fatty acids and glucose depending on whether the body is fed or fasted. PFKFB2, the heart-enriched isoform of the bifunctional PFK-2/FBPase-2 enzyme, is central to this fuel switching. When researchers deleted PFKFB2 specifically in mouse hearts, the normal metabolic adjustment to fasting was blunted. In control hearts, fasting lowered the activity of the enzyme that feeds pyruvate into mitochondria by about 38%, and reduced pyruvate-driven respiration by about 15%. Hearts lacking PFKFB2 failed to make this adjustment properly.6Journal of the American Heart Association. PFKFB2 is Pivotal for Metabolic Flexibility and Differential Glucose Utilization Without the ability to dial glycolysis up and down in response to nutrient availability, the heart becomes metabolically rigid, a condition linked to cardiac dysfunction.
Diabetes appears to compromise this system. Both type 1 diabetes and a high-fat diet reduce PFKFB2 protein levels in the heart without affecting the gene’s transcript levels, suggesting the protein is being degraded faster rather than produced less. The loss of PFKFB2 protein impairs the heart’s capacity to regulate glycolysis dynamically and causes a buildup of early glycolytic intermediates. While this shift might conserve glucose for the rest of the body during fasting, in the context of diabetes it represents a pathological impairment.7PubMed Central. Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity
PFKFB2 also appears to protect the heart during acute injury. During ischemia-reperfusion injury (the damage that occurs when blood flow is restored after a heart attack), PFKFB2 overexpression in mice improved heart function and inhibited ferroptosis, a form of iron-driven cell death. The protective mechanism involved activation of the AMPK signaling pathway.8Journal of Cardiovascular Pharmacology. PFKFB2 Inhibits Ferroptosis in Myocardial Ischemia/Reperfusion Injury Through Adenosine Monophosphate–Activated Protein Kinase Activation Separately, under low-oxygen conditions, PFKFB2 activated the glycolytic energy pathway that helps cardiomyocytes survive hypoxia, and this activation reduced cardiac cell death.9International Heart Journal. HIF-1/AKT Signaling-Activated PFKFB2 Alleviates Cardiac Dysfunction and Cardiomyocyte Apoptosis in Response to Hypoxia
The Nuclear Side Job
For decades, FBP2 was catalogued as a cytoplasmic metabolic enzyme. That picture changed when researchers found FBP2 inside the nucleus, where it does things that have nothing to do with sugar metabolism. In lung cancer cells and cardiomyocytes, FBP2’s nuclear presence tracks with specific phases of the cell cycle: it correlates with the appearance of cyclins associated with DNA replication and preparation for division. Proteomic analysis of FBP2’s binding partners in the nucleus revealed proteins involved in cell cycle regulation, processing of messenger RNA, and maintaining the structural integrity of genomic DNA.10PubMed Central. Cell cycle-dependent expression and subcellular localization of fructose 1,6-bisphosphatase
The most striking nuclear role identified so far is in sarcoma suppression. In sarcoma cells, nuclear FBP2 physically localizes with the c-Myc transcription factor at the gene encoding TFAM, a key driver of mitochondrial biogenesis. By sitting on this locus, FBP2 represses c-Myc-dependent TFAM expression, which constrains the cell’s ability to build new mitochondria and carry out oxidative phosphorylation. This tumor-suppressive activity is completely independent of FBP2’s enzymatic function: a catalytically dead version of FBP2 still inhibits mitochondrial biogenesis and slows tumor growth.11Cell Metabolism. Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis So FBP2 fights cancer through two channels simultaneously: in the cytoplasm, it slows glycolysis by opposing the metabolic rewiring that tumors rely on; in the nucleus, it strangles the mitochondrial supply line that feeds oxidative energy production.
FBP2 Silencing Across Cancers
Cancer cells are notorious for ramping up glycolysis even when oxygen is plentiful, a phenomenon that requires sidelining enzymes like FBP2 that would otherwise slow glucose consumption. The silencing of FBP2 turns out to be widespread. In soft tissue sarcomas, FBP2 expression is lost across a broad spectrum of subtypes, making it an apparently shared metabolic feature of these diverse tumors.12PubMed Central. Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis Loss of FBP1 and FBP2 has also been documented in renal carcinoma and liver cancer, where both isozymes suppress tumor growth through both enzymatic and non-enzymatic mechanisms.13Cancer Research. Abstract SY19-02: Metabolic tumor suppressors and disease progression
In gastric cancer, FBP2 was downregulated in about 86% of tumor tissues studied, and patients whose tumors had absent or low FBP2 expression had significantly worse survival outcomes.14PubMed Central. Decreased fructose-1,6-bisphosphatase-2 expression promotes glycolysis and growth in gastric cancer cells A similar pattern holds in hepatocellular carcinoma linked to hepatitis B virus infection: FBP2 messenger RNA levels were significantly lower in tumor tissue than in normal liver, and higher FBP2 expression was associated with better patient survival.15PubMed Central. Genetic Variants of UGP2 and FBP2 in the Glycolysis Pathway Independently Predict Survival of Patients with HBV-Related Hepatocellular Carcinoma These findings are consistent with the view that FBP2 acts as a metabolic tumor suppressor: when cancer cells silence it, they gain a growth advantage; when researchers force its expression back on, tumor growth slows.
One important wrinkle involves aldolase A, a glycolytic enzyme that cancer cells often overproduce. Aldolase A can bind FBP2 and potentially block its anti-cancer activity. Intriguingly, this interaction is specific to the muscle isozyme: FBP2 binds aldolase A more than ten times more strongly than FBP1 does.16Advances in Biological Regulation. Fructose 1,6-bisphosphatase as a promising target of anticancer treatment This raises the possibility that tumors expressing high aldolase A may neutralize FBP2 even without silencing it genetically, adding another layer of metabolic manipulation.
PFKFB2 in Pancreatic Cancer
While FBP2 generally acts as a brake on tumor growth, the bifunctional enzyme PFKFB2 can play a different role in certain cancers. In pancreatic adenocarcinoma cells, PFKFB2 is required for maintaining steady-state levels of fructose-2,6-bisphosphate, the potent glycolytic activator. Knocking PFKFB2 down reduced glycolytic activity and slowed cell proliferation. Adding a layer of complexity, different splice variants of PFKFB2 messenger RNA localize to different compartments within the cell, and the cytoplasmically localized variant drives a greater increase in fructose-2,6-bisphosphate and glucose uptake than the variant that localizes to the nucleus.17PubMed. PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells In pancreatic cancer, then, PFKFB2 looks more like an enabler of tumor metabolism than a suppressor, which underscores that the bifunctional enzyme and the standalone FBP2 isozyme can have opposing relationships with cancer despite sharing overlapping metabolic territory.
FBP2 in the Brain
Neurons and astrocytes have a deeply cooperative metabolic relationship. Neurons are voracious energy consumers but limited in their glycolytic capacity, so neighboring astrocytes help by processing glucose and shuttling metabolic intermediates to them. FBP2 is part of how this partnership gets fine-tuned. In astrocytes, neuronal extracellular vesicles, small membrane-bound packets released by neurons, reduce FBP2 at both the messenger RNA and protein level. The drop in FBP2 messenger RNA happens remarkably fast, within about two hours of exposure, and the protein reduction that follows involves signaling through the PI3K/Akt/Cdk pathway.
But the story is not simply about eliminating FBP2. The vesicles also shift the balance of FBP2 from tetramers toward dimers, and this shift allows the remaining FBP2 dimers to associate with mitochondria. That mitochondrial association appears to be protective: when calcium floods into the cell, which can depolarize mitochondrial membranes to dangerous levels, the FBP2-mitochondria interaction keeps the depolarization within a non-damaging range.18Scientific Reports. Neuronal extracellular vesicles influence the expression, degradation and oligomeric state of fructose 1,6-bisphosphatase 2 in astrocytes affecting their glycolytic capacity So neurons use FBP2 as a remote control dial in astrocytes: they lower its overall amount to boost astrocytic glycolysis (generating more fuel for neurons) while simultaneously redirecting the remaining FBP2 to protect astrocytic mitochondria from excitotoxic stress. The sophistication of this cross-talk suggests FBP2 is a key player in how the brain manages its energy supply at the single-cell level.
Targeting These Enzymes With Drugs
The involvement of both FBP2 and PFKFB2 in cancer, diabetes, and cardiac disease has predictably attracted drug hunters. On the diabetes side, the target is FBP1 rather than FBP2, since the liver isozyme drives gluconeogenesis and excess hepatic glucose production is a hallmark of type 2 diabetes. Lead compounds targeting FBP1 have reached impressive potency in preclinical models.19Taylor & Francis Online (Arch Physiol Biochem). Fructose-1,6-bisphosphatase as a therapeutic target for type 2 diabetes: from molecular mechanisms to clinical translation
On the cancer side, PFKFB2 and its close relative PFKFB3 are being targeted with small-molecule inhibitors to starve tumors of glycolytic fuel. An AI-driven drug screening platform recently identified a compound called B2 that inhibits PFKFB2 with an IC50 of about 3.3 micromolar and PFKFB3 at roughly 12 micromolar. In renal cancer cells expressing both enzymes, B2 reduced glycolysis and glycolytic capacity, decreased levels of downstream glycolytic intermediates, and caused a buildup of fructose-6-phosphate upstream of the block, consistent with effective inhibition of the glycolytic pathway.20PubMed Central. Mechanistic studies of PFKFB2 reveals a novel inhibitor of its kinase activity These are early-stage results, but they demonstrate that the kinase domain of the bifunctional enzyme is a druggable target.
The challenge with any metabolic drug target is selectivity. FBP2’s tumor-suppressive role means that inhibiting it broadly could be counterproductive in some cancers, even as boosting its activity might be therapeutic. For PFKFB2, the dual-domain architecture creates an opportunity: a drug that blocks the kinase activity (PFK-2) without affecting the phosphatase activity (FBPase-2) could reduce fructose-2,6-bisphosphate production and slow glycolysis in tumors, while sparing normal metabolic regulation in healthy tissues. Whether that selectivity can be achieved in practice remains an open question, but the structural differences among the four PFKFB family members at least offer potential footholds for isoform-specific drug design.
Muscle Development and Regeneration
FBP2 expression in skeletal muscle is not static across the lifespan; it is regulated during both embryonic muscle development and adult muscle regeneration. The nuclear receptor Nur77, a transcription factor involved in metabolic gene control, drives FBP2 expression as one of its target genes. In mice with muscle-specific Nur77 deletion, FBP2 expression was reduced in skeletal muscle, and these animals showed impaired muscle growth during developmental myogenesis and during regeneration after injury.21PLOS ONE. Nur77 deletion impairs muscle growth during developmental myogenesis and muscle regeneration in mice While FBP2 was not the only downstream target affected, its inclusion in the Nur77 program links it to the broader machinery of muscle growth and repair. This connection hints that FBP2 may be more than a housekeeping enzyme in muscle: it could be part of the metabolic reprogramming that accompanies the shift from quiescent satellite cells to actively proliferating and differentiating muscle fibers.
The evolutionary conservation of FBP2 across vertebrates supports the idea that its functions extend well beyond simple sugar metabolism. The muscle isozyme has been described as one of the ancient, conserved enzymes of carbohydrate metabolism, and its ubiquitous expression across tissues that were not traditionally considered gluconeogenic was itself a surprise that prompted much of the recent research into its non-catalytic roles.22Advances in Biological Regulation. Fructose-1,6-bisphosphatase: From a glucose metabolism enzyme to multifaceted regulator of a cell fate The discovery that an enzyme can moonlight as a transcriptional regulator, a mitochondrial guardian, and a tumor suppressor while also doing its day job of splitting sugar phosphates is a reminder that metabolic enzymes are not merely cogs in a biochemical pathway. They are multifunctional proteins whose roles expand every time someone looks at them in a new cellular context.